Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - JCR Pharmaceuticals

Next Previous
Drug Profile

Somatropin - JCR Pharmaceuticals

Alternative Names: Growject; JR-142; JR-401A; JR-401G; JR-401S; JR-401X; Redalsomatropin alfa - JCR Pharmaceuticals; Somatropin-long-acting - JCR Pharmaceuticals

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JCR Pharmaceuticals; Savient Pharmaceuticals
  • Developer JCR Pharmaceuticals
  • Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Preclinical Growth disorders

Most Recent Events

  • 09 Sep 2026 Somatropin is still in Preclinical trials in Growth disorders in Japan (unspecified route) (JCR Pharmaceuticals pipeline, September 2026)
  • 23 Dec 2024 Phase-III clinical trials in Somatotropin deficiency (In children) in Japan (SC) (jRCT2031240282)
  • 11 Jul 2023 Phase-II clinical trials in Somatotropin deficiency (SC) (JCR Pharmaceuticals pipeline, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top